Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16029352rdf:typepubmed:Citationlld:pubmed
pubmed-article:16029352lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:16029352lifeskim:mentionsumls-concept:C0023283lld:lifeskim
pubmed-article:16029352lifeskim:mentionsumls-concept:C1145701lld:lifeskim
pubmed-article:16029352lifeskim:mentionsumls-concept:C0023271lld:lifeskim
pubmed-article:16029352pubmed:issue1lld:pubmed
pubmed-article:16029352pubmed:dateCreated2005-7-20lld:pubmed
pubmed-article:16029352pubmed:abstractTextExisting systemic treatments for New World cutaneous leishmaniasis (CL) caused by Leishmania (vianna) braziliensis are unsatisfactory. Liposomal amphotericin B has been used extensively for the treatment of visceral leishmaniasis, but in few cases of CL, and an appropriate regimen for CL has not been described. We successfully treated a patient with multiple L. braziliensis CL lesions acquired in Belize. Liposomal amphotericin B (AmBisome) was given to our patient as an inpatient for seven daily doses of 3 mg kg(-1) day(-1) and then as an outpatient at 3 mg kg(-1) twice weekly for a further three weeks, a total of 40 mg kg(-1). Liposomal amphotericin offers a well-tolerated alternative to pentavalent antimony or amphotericin B deoxycholate for the systemic treatment of New World CL.lld:pubmed
pubmed-article:16029352pubmed:languageenglld:pubmed
pubmed-article:16029352pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16029352pubmed:citationSubsetIMlld:pubmed
pubmed-article:16029352pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16029352pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16029352pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16029352pubmed:statusMEDLINElld:pubmed
pubmed-article:16029352pubmed:monthJullld:pubmed
pubmed-article:16029352pubmed:issn0007-0963lld:pubmed
pubmed-article:16029352pubmed:authorpubmed-author:BrownMMlld:pubmed
pubmed-article:16029352pubmed:authorpubmed-author:BoyleJJlld:pubmed
pubmed-article:16029352pubmed:authorpubmed-author:DavidsonR NRNlld:pubmed
pubmed-article:16029352pubmed:authorpubmed-author:NoursadeghiMMlld:pubmed
pubmed-article:16029352pubmed:issnTypePrintlld:pubmed
pubmed-article:16029352pubmed:volume153lld:pubmed
pubmed-article:16029352pubmed:ownerNLMlld:pubmed
pubmed-article:16029352pubmed:authorsCompleteYlld:pubmed
pubmed-article:16029352pubmed:pagination203-5lld:pubmed
pubmed-article:16029352pubmed:meshHeadingpubmed-meshheading:16029352...lld:pubmed
pubmed-article:16029352pubmed:meshHeadingpubmed-meshheading:16029352...lld:pubmed
pubmed-article:16029352pubmed:meshHeadingpubmed-meshheading:16029352...lld:pubmed
pubmed-article:16029352pubmed:meshHeadingpubmed-meshheading:16029352...lld:pubmed
pubmed-article:16029352pubmed:meshHeadingpubmed-meshheading:16029352...lld:pubmed
pubmed-article:16029352pubmed:meshHeadingpubmed-meshheading:16029352...lld:pubmed
pubmed-article:16029352pubmed:meshHeadingpubmed-meshheading:16029352...lld:pubmed
pubmed-article:16029352pubmed:meshHeadingpubmed-meshheading:16029352...lld:pubmed
pubmed-article:16029352pubmed:meshHeadingpubmed-meshheading:16029352...lld:pubmed
pubmed-article:16029352pubmed:meshHeadingpubmed-meshheading:16029352...lld:pubmed
pubmed-article:16029352pubmed:year2005lld:pubmed
pubmed-article:16029352pubmed:articleTitleSuccessful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis.lld:pubmed
pubmed-article:16029352pubmed:affiliationDepartment of Infection & Tropical Medicine, Northwick Park Hospital, Harrow, UK. michael.brown@lshtm.ac.uklld:pubmed
pubmed-article:16029352pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16029352pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16029352lld:pubmed